Home » Stocks » HCM

HUTCHMED (China) Limited (HCM)

Stock Price: $39.42 USD -0.98 (-2.41%)
Updated Jul 26, 2021 10:06 AM EDT - Market open
Market Cap 6.98B
Revenue (ttm) 257.96M
Net Income (ttm) n/a
Shares Out 172.82M
EPS (ttm) -1.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $39.42
Previous Close $40.39
Change ($) -0.98
Change (%) -2.41%
Day's Open 39.22
Day's Range 38.70 - 39.60
Day's Volume 54,259
52-Week Range 23.67 - 43.36

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The European Medicines Agency (EMA) has validated and accepted Hutchmed (China) Limited's (NASDAQ: HCM) marketing application seeking approval for surufatinib for pancreatic and extra-pancreatic (non-pa...

1 week ago - Benzinga

– EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors –

1 week ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor of HUTCHMED (China) Limited (HCM).

1 week ago - Zacks Investment Research

Hutchison China MediTech (HCM) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made i...

1 week ago - Zacks Investment Research

Hutchmed (China) Limited (NASDAQ: HCM) announces the first commercial sale in China of Orpathys (savolitinib), a selective small-molecule inhibitor of MET, a receptor tyrosine kinase. It follows less th...

Other stocks mentioned: AZN
1 week ago - Benzinga

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces the first commercial sale in China of ...

1 week ago - GlobeNewsWire

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 12, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM, HKEX:13) today announces the full exercise of th...

2 weeks ago - GlobeNewsWire

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., July 05, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) has initiated a Phase I study of HMPL-295, its investigati...

2 weeks ago - GlobeNewsWire

HONG KONG and SHANGHAI, China and & FLORHAM PARK, N.J., July 02, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the ...

3 weeks ago - GlobeNewsWire

– U.S. FDA has assigned a target action date of April 30, 2022 –

3 weeks ago - GlobeNewsWire

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 30, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM: HCM) today announces the listing of its ordi...

3 weeks ago - GlobeNewsWire

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM: HCM) today announces the pricing of its glob...

1 month ago - GlobeNewsWire

– First selective MET inhibitor approval in China in this setting –

1 month ago - GlobeNewsWire

– Second New Drug Application (“NDA”) approved for Sulanda in China –

1 month ago - GlobeNewsWire

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 18, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces the launch of its Hong Ko...

1 month ago - GlobeNewsWire

– HUTCHMED will review these highlights as part of its company update audio call and webcast on Wednesday, May 26 at 9 a.m. EDT to discuss data disclosures, its PD-1/L1 combination study strategy and pr...

2 months ago - GlobeNewsWire

– HUTCHMED will hold a webcast on Wednesday, May 26 at 8 a.m. EDT to provide updates on recent progress and upcoming milestones – – HUTCHMED will hold a webcast on Wednesday, May 26 at 8 a.m. EDT to pro...

2 months ago - GlobeNewsWire

HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM: HCM), formerly known as Hutchison China MediTech Limited, announces that, furthe...

2 months ago - GlobeNewsWire

First NDA submission by HUTCHMED in the U.S.; product launch preparations underway First NDA submission by HUTCHMED in the U.S.; product launch preparations underway

2 months ago - GlobeNewsWire

— Single-arm study in ~180 patients, with ORR as primary endpoint —

2 months ago - GlobeNewsWire

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

3 months ago - GlobeNewsWire

Hutchison China MediTech (HCM) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

3 months ago - Zacks Investment Research

— HMPL-306 is the sixth innovative oncology drug candidate discovered in house by HUTCHMED to enter into global development — — HMPL-306 is the sixth innovative oncology drug candidate discovered in hou...

3 months ago - GlobeNewsWire

Hutchison China MediTech (NASDAQ: HCM) has agreed to sell its non-core and non-consolidated over-the-counter drug joint venture business to GL Capital Group. The sale of our shares in the joint venture,...

4 months ago - Benzinga

Allows focus on China and global clinical development and market launches of key Oncology/Immunology assets Allows focus on China and global clinical development and market launches of key Oncology/Immu...

4 months ago - GlobeNewsWire

Hutchison China MediTech (NASDAQ: HCM) has initiated a Phase 1b/2 study of surufatinib combined with BeiGene Ltd's (NASDAQ: BGNE) tislelizumab in patients with advanced solid tumors in the U.S. and Euro...

Other stocks mentioned: BGNE
4 months ago - Benzinga

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 24, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) has initiated a Phase Ib/II study of surufatinib in comb...

4 months ago - GlobeNewsWire

Company to Host Annual Results Call & Webcast Today at 1 p.m. GMT / 8 a.m. EST / 9 p.m. HKT Company to Host Annual Results Call & Webcast Today at 1 p.m. GMT / 8 a.m. EST / 9 p.m. HKT

4 months ago - GlobeNewsWire

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its final results for the year e...

5 months ago - GlobeNewsWire

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the final analysis of savolitinib in Pha...

6 months ago - GlobeNewsWire

HONG KONG, SHANGHAI, China, SAN DIEGO & FLORHAM PARK, N.J., Jan. 10, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Inmagene Biopharmaceuticals (“Inmagene”) ...

6 months ago - GlobeNewsWire

– Sulanda® is Chi-Med's first oncology drug brought to market without a partnership and the company's second oncology drug approved in China –

6 months ago - GlobeNewsWire

– Company plans to complete rolling submission in the first half of 2021 –

6 months ago - GlobeNewsWire

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executiv...

7 months ago - GlobeNewsWire

Pharmaceuticals is the only sector that has all three characteristics foreign investors are looking for in Chinese investments: an industry that will consolidate, pro-growth policy reform and support an...

Other stocks mentioned: BGNE
8 months ago - GuruFocus

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

8 months ago - GlobeNewsWire

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that initial analysis of the first ...

8 months ago - GlobeNewsWire

― Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (“NET”) ―

10 months ago - GlobeNewsWire

HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that its New Drug Application (“N...

10 months ago - GlobeNewsWire

HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) has initiated FRESCO-2, a Phase III registration ...

10 months ago - GlobeNewsWire

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, it...

10 months ago - GlobeNewsWire

HONG KONG and FLORHAM PARK, N.J., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the studies of sur...

11 months ago - GlobeNewsWire

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that it received scientific advice fro...

11 months ago - GlobeNewsWire

Hutchison China MediTech Limited (HCM) CEO Christian Hogg on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

– Strong global pipeline progress – three U.S. FDA 1 Fast Track Designations; surufatinib U.S. NDA 2 preparations underway; and initiation of global Phase III for fruquintinib –

11 months ago - GlobeNewsWire

HONG KONG and FLORHAM PARK, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announced that the China National Medical Products Administra...

11 months ago - GlobeNewsWire

HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) and Eli Lilly and Company (“Lilly”) today announce an am...

11 months ago - GlobeNewsWire

— HMPL-306 is the ninth innovative oncology drug candidate discovered in house by Chi-Med —

1 year ago - GlobeNewsWire

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

1 year ago - GlobeNewsWire

LONDON, June 18, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Des...

1 year ago - GlobeNewsWire

About HCM

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company is developing Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fru... [Read more...]

Industry
Biotechnology
CEO
Christian Hogg
Employees
1,280
Stock Exchange
NASDAQ
Ticker Symbol
HCM
Full Company Profile

Financial Performance

In 2020, HUTCHMED's revenue was $227.98 million, an increase of 11.27% compared to the previous year's $204.89 million. Losses were -$125.73 million, 18.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for HUTCHMED stock is "Strong Buy." The 12-month stock price forecast is 41.40, which is an increase of 5.04% from the latest price.

Price Target
$41.40
(5.04% upside)
Analyst Consensus: Strong Buy